US Normative Data for the Adult ADHD Self-Report Scale (ASRS-V1.1)

December 21, 2017

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Introduction: The Adult ADHD Self-Report Scale (ASRS-v1.1) was developed to assess symptoms most predictive of attention-deficit hyperactivity disorder (ADHD). Although the ASRS-v1.1 has been well-established in clinical practice, normative data for the US are not yet available. The current study estimated norms for the ASRS-v1.1 from a large, representative sample of US adults.

Methods: US adults who participated in the National Health and Wellness Survey were re-contacted to participate in this study. In October 2013, respondents completed the ASRS-v1.1, an 18-item symptom checklist. Each item is scored 0-3 based on a frequency basis of "never" to "very often". Bivariate differences in total scores by age, sex, Hispanic origin, and race were examined; a full factorial multiple regression model tested for interactions among these characteristics.

Results: Overall, 22,397 adults completed the survey. On average, the sample was 51.1 (SD=15.8) years old, female (54.4%), white (82.7%; 8.9% black, 8.5% other), and identified as non-Hispanic (93.7%; 5.9% Hispanic, .4% declined to answer). The average ASRS-v1.1 total score for the full sample was 2.0 (SD=3.2). Significant differences were found by age (18-29=3.0, 30-39=2.6, 40-49=2.3, 50-64=1.8, 65+=1.2; p<.001), sex (male=1.9, female=2.1; p<.001), Hispanic origin (Hispanic=2.8, non-Hispanic=2.0; p<.001), and race (white=2.0, black=2.2, other=2.5; p<.001).

Discussion: Findings suggest that ASRS-v1.1 scores vary by demographics. Future studies should consider the potential effects of demographics on the ASRS v1.1 Screener. Normative data generated for the ASRS-v1.1 in this study will allow comparisons with individual's scores to better support the screening of ADHD symptoms.

Lenard Adler, MD; Stephen Faraone, PhD; Phillip Sarocco, RPh, MSc; Norman Atkins, PhD, MBA; Alexandra Khachatryan, MPH
Sponsoring Organization: 
Shire LLC
PCN Topics: